Locus Biosciences is a clinical-stage biotechnology company developing precision antimicrobial medicines for therapeutic indications across; infectious disease, immunology & oncology. Their high-throughput discovery automation platform and powerful synthetic biology methods enable rapid and modular drug product development against any target bacterial species. The crPhage platform selectively removes bacterial species and strains without disrupting the microbiome or inducing toxic side effects. crPhage is a CRISPR-Cas3 enhanced bacteriophage product that targets and kills specific bacteria by irreversibly destroying their DNA while leaving the many species of good bacteria in the body unharmed. This technology can be used to address any disease, both in infectious disease and the microbiome, where pathogenic bacteria play a role.